Abstract
In eight subjects with Parkinson's disease under an optimal daily dose of l-dopa, acute administration of MIF-I (200 mg i.v.) did not ameliorate either the total disability score or the intellectual test PM 38 when evaluated in comparison with the effect induced by acute administration of a placebo. Also concomitant evaluation of the effect of MIF-I on the secretion of anterior pituitary hormones which are under dopaminergic control i.e., growth hormone and prolactin, did not reveal any potentiation of the l-dopa-induced stimulus.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barbeau, A.: Potentiation of levodopa effect by intravenous l-prolyl-l-leucyl-glycine amide in man. Lancett 1975 II, 683
Canal, N., Müller, E. E., Smirne, S., Panerai, A. E., Musch, B.: Dopaminergic control of growth hormone (GH) release in Parkinson's disease. 11th World Cong. Neurol., Amsterdam, Sept. 11–16, 1977, p. 129 [Abstr.]. Amsterdam: Excerpta Medica 1977
Caraceni, T. A., Celano, I., Parati, E., Girotti, F.: Bromocriptine alone or associated with l-dopa, plus Benserazide in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 40, 1142–1146 (1977)
Celis, M. E., Taleisnik, D., Walter, R.: Regulation of formation and proposed structure of the factor inhibiting the release of melanocyte-stimulating hormone. Proc. Natl. Acad. Sci. USA 68, 1428–1433 (1971)
Chase, T. N., Woods, A. C., Lipton, M. A., Morris, C. E.: Hypothalamic releasing factors and Parkinson's disease. Arch. Neurol. 31, 55–56 (1974)
Cox, B., Kastin, A. J., Schnieden, H.: A comparison between a melanocyte-stimulating hormone inhibitory factor (MIF-I) and substances known to activate central dopamine receptors. Eur. J. Pharmacol. 36, 141–147 (1976)
Crowley, T. J., Hydinger, M.: MIF, TRH, and simian social and motor behavior. Pharmacol. Biochem. Behav. 5 [Suppl. 1], 79–87 (1976)
Duvoisin, R. C.: The evaluation of extrapyramidal disease. In: Monoamines, noyeaux gris centraux et syndrome de parkinson, J. de Ajuriaguerra, ed., pp. 313–325. Geneve: Georye/Paris: Masson 1971
Eddy, R. L., Parker, K. M.: Effect of aromatic amino-acid decarboxylase inhibitor on the growth hormone refractory period. 58th Annu. Mtg. Endocrine Soc., San Francisco, California. Abstract 469 (1976)
Fischer, P. A., Schneider, E., Jacobi, P., Maxion, H.: Effect of melanocyte-stimulating hormone release inhibiting factor (MIF) in Parkinson's syndrome. Eur. Neurol. 12, 360–368 (1974)
Frantz, A., Kleinberg, D., Noel, G.: Studies on prolactin in man. Recent Prog. Horm. Res. 28, 527–590 (1972)
Kastin, J. A., Barbeau, A.: Preliminary clinical studies with l-prolyl-l-leucyl-glycine amide in Parkinson's disease. C. A. M. J. 107, 1079–1081 (1972)
Kastin, J. A., Ehrensing, R. H., Schalch, D. S., Anderson, M. S.: Improvement in mental depression with decreased thyrotropin response after administration of thyrotropin releasing hormone. Lancet 1972 II, 740–742
Kastin, J. A., Gual, C., Schally, A. V.: Clinical experience with hypothalamic releasing hormones. II. Luteinizing hormone-releasing hormone and other hypophysiotropic hormones. Recent Prog. Horm. Res. 28, 201–227 (1972)
Kastin, J. A., Plotnikoff, N. P., Schally, A. V., Sandman, C. A.: Endocrine and CNS effects of hypothalamic peptides and MSH. In: Review of neuroscience, Vol. 2, S. Ehrenpreis and I. J. Kopin, eds., pp. 111–148. New York: Raven 1976
Kostrzewa, R. M., Spirtes, M. A., Klara, J. W., Christensen, C. W., Kastin, J. A., Joh, T. H.: Effects of l-prolyl-l-leucyl-glycine amide (MIF-I) on dopaminergic neurons. Pharmacol. Biochem. Behav. 5 [Suppl. 1], 125–127 (1976)
Meites, J.: Catecholamines and prolactin secretion. In: Non striatal dopaminergic neurons. Adv. Biochem. Psychopharmacol. Vol. 16, E. Costa, G. L. Gessa eds. pp. 139–146. New York: Raven 1977
Müller, E. E., Liuzzi, A., Cocchi, D., Panerai, A. E., Opizzi, G., Locatelli, V., Mantegazza, P., Silvestrini, F., Chiodini, P. G.: Role of dopaminergic receptors in the regulation of growth hormone secretion. In: Nonstriatal dopaminergic neurons. Adv. Biochem. Psychopharmacol. 16, E. Costa, G. L. Gessa eds., pp. 127–138. New York: Raven 1977
Pfaff, D. W.: Luteinizing hormone releasing factor potentiates lordosis behavior in hypophysectomized, ovariectomized rats. Science 182, 1148–1149 (1973)
Plotnikoff, N. P., Kastin, J. A., Anderson, M. S., Schally, A. V.: Dopa potentiation by a hypothalamic factor, MSH release inhibiting hormone (MIF). Life Sci. 10, 1279–1282 (1971)
Plotnikoff, N. P., Kastin, J. A., Anderson, M. S., Schally, A. V.: Oxotremorine antagonism by a hypothalamic hormone, melanocyte-stimulating hormone release-inhibiting factor, MIF. Proc. Soc. Exp. Biol. Med. 140, 811–814 (1972)
Plotnikoff, N. P., Kastin, J. A., Anderson, M. S., Schally, A. V.: Deserpidine antagonism by a tripeptide, l-prolyl-l-leucyl-glycinamide. Neuroendocrinology 2, 67–71 (1973)
Plotnikoff, N. P., Minard, F. N., Kastin, J. A.: Dopa potentiation in ablated animals and brain levels of biogenic amines in intact animals after prolyl-leucylglycinamide. Neuroendocrinology 14, 271–279 (1974)
Plotnikoff, N. P., Kastin, J. A.: Pharmacological studies with a tripeptide, prolyl-leucyl glycine amide. Arch. Int. Pharmacodyn. Ther 211, 211–224 (1974)
Raven, S. C.: Standard progressive matrices. London: Lewis 1938
Rezek, M., Havlicek, V., Hughes, K. R., Friesen, H.: Central site of action of somatostatin (SRIF): role of hippocampus. Neuropharmacology 15, 499–504 (1976)
Sakamoti, A.: Hypersensitivity induced in albino mice by melanocyte-stimulating hormone. Nature 211, 1370 (1966)
Schalch, S., Parker, M.: A sensitive double-antibody immunoassay for human growth hormone in plasma. Nature 203, 1141–1142 (1964)
Webster, D. D.: Critical analysis of the disability in Parkinson's disease. Med. Treatment (N.Y.) 5, 257–282 (1968)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Caraceni, T., Parati, E.A., Girotti, F. et al. Failure of MIF-I to affect behavioral responses in patients with parkinson's disease under l-dopa therapy. Psychopharmacology 63, 217–222 (1979). https://doi.org/10.1007/BF00433553
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00433553